Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial
Li Yue,1 Sheng Luo,2 Yiwen Wang,1 Chia-Ning Wang,1 Héctor José Dueñas,3 Vladimir Skljarevski4 1Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, PR China; 2Department of Pain Treatment, Beijing Hospital of the Ministry of Health, Beijing, PR China; 3Eli...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2019
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/939aa549f2e74d6ca13ae2fb7dd14a9b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:939aa549f2e74d6ca13ae2fb7dd14a9b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:939aa549f2e74d6ca13ae2fb7dd14a9b2021-12-02T03:14:54ZClinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial1179-156Xhttps://doaj.org/article/939aa549f2e74d6ca13ae2fb7dd14a9b2019-03-01T00:00:00Zhttps://www.dovepress.com/clinical-meaningfulness-of-duloxetines-effect-in-chinese-patients-with-peer-reviewed-article-OARRRhttps://doaj.org/toc/1179-156XLi Yue,1 Sheng Luo,2 Yiwen Wang,1 Chia-Ning Wang,1 Héctor José Dueñas,3 Vladimir Skljarevski4 1Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, PR China; 2Department of Pain Treatment, Beijing Hospital of the Ministry of Health, Beijing, PR China; 3Eli Lilly de Mexico, Mexico City, Mexico; 4Eli Lilly and Company, Indianapolis, IN, USA Purpose: To evaluate the analgesic effect of duloxetine in Chinese patients with osteoarthritis (OA) of the knee/hip at individual patient level and report the relationship between pain intensity reduction, overall improvement, and physical functioning.Patients and methods: Post hoc analysis of 13-week, phase 3, parallel-group, randomized, placebo-controlled study of duloxetine in Chinese patients with OA pain. Patients were randomized (1:1, computer-generated, interactive web-response system) to duloxetine (60 mg once daily, n=202) or placebo (n=207). Patients, investigators, and study staff were blinded throughout the study. Duloxetine’s efficacy was evaluated using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and the Osteoarthritis Research Society International and Outcome Measures in Rheumatology (OARSI-OMERACT) responder criteria. Analyses were conducted on all randomized patients with a baseline and at least one post-baseline observation.Results: At study endpoint, the percentage of patients experiencing ≥30% pain intensity reduction (30% responders) was significantly higher in the duloxetine group than in the placebo group (63.4% vs 49.7%; P=0.008). The percentage of patients experiencing ≥50% pain intensity reduction (50% responders) in the duloxetine group was numerically higher than in the placebo group (42.8% vs 34.5%; P=0.098). Most of the 30% and 50% responders to duloxetine treatment felt either “very much improved” or “much improved” on the Patient Global Impression-Improvement at endpoint. The 30% and 50% responders to duloxetine treatment also experienced greater improvements in the Western Ontario and McMaster Universities Osteoarthritis Index physical function scores at endpoint compared with non-responders. The overall percentage of OARSI-OMERACT responders was significantly higher in the duloxetine group vs the placebo group (70.1% vs 54.9%; P=0.003).Conclusion: Based on IMMPACT and OARSI-OMERACT criteria, the analgesic effect of duloxetine was associated with clinically relevant benefits in Chinese patients with OA of the knee/hip.ClinicalTrials.gov identifier: NCT01931475. Keywords: Chinese, chronic pain, duloxetine, clinical meaningfulness, efficacy, osteoarthritisYue LLuo SWang YWang CNDueñas HJSkljarevski VDove Medical PressarticleChineseChronic painDuloxetineIMMPACTOMERACT-OARSIOsteoarthritisDiseases of the musculoskeletal systemRC925-935ENOpen Access Rheumatology: Research and Reviews, Vol Volume 11, Pp 67-76 (2019) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Chinese Chronic pain Duloxetine IMMPACT OMERACT-OARSI Osteoarthritis Diseases of the musculoskeletal system RC925-935 |
| spellingShingle |
Chinese Chronic pain Duloxetine IMMPACT OMERACT-OARSI Osteoarthritis Diseases of the musculoskeletal system RC925-935 Yue L Luo S Wang Y Wang CN Dueñas HJ Skljarevski V Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
| description |
Li Yue,1 Sheng Luo,2 Yiwen Wang,1 Chia-Ning Wang,1 Héctor José Dueñas,3 Vladimir Skljarevski4 1Lilly Suzhou Pharmaceutical Co. Ltd. Shanghai Branch, Shanghai, PR China; 2Department of Pain Treatment, Beijing Hospital of the Ministry of Health, Beijing, PR China; 3Eli Lilly de Mexico, Mexico City, Mexico; 4Eli Lilly and Company, Indianapolis, IN, USA Purpose: To evaluate the analgesic effect of duloxetine in Chinese patients with osteoarthritis (OA) of the knee/hip at individual patient level and report the relationship between pain intensity reduction, overall improvement, and physical functioning.Patients and methods: Post hoc analysis of 13-week, phase 3, parallel-group, randomized, placebo-controlled study of duloxetine in Chinese patients with OA pain. Patients were randomized (1:1, computer-generated, interactive web-response system) to duloxetine (60 mg once daily, n=202) or placebo (n=207). Patients, investigators, and study staff were blinded throughout the study. Duloxetine’s efficacy was evaluated using the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) and the Osteoarthritis Research Society International and Outcome Measures in Rheumatology (OARSI-OMERACT) responder criteria. Analyses were conducted on all randomized patients with a baseline and at least one post-baseline observation.Results: At study endpoint, the percentage of patients experiencing ≥30% pain intensity reduction (30% responders) was significantly higher in the duloxetine group than in the placebo group (63.4% vs 49.7%; P=0.008). The percentage of patients experiencing ≥50% pain intensity reduction (50% responders) in the duloxetine group was numerically higher than in the placebo group (42.8% vs 34.5%; P=0.098). Most of the 30% and 50% responders to duloxetine treatment felt either “very much improved” or “much improved” on the Patient Global Impression-Improvement at endpoint. The 30% and 50% responders to duloxetine treatment also experienced greater improvements in the Western Ontario and McMaster Universities Osteoarthritis Index physical function scores at endpoint compared with non-responders. The overall percentage of OARSI-OMERACT responders was significantly higher in the duloxetine group vs the placebo group (70.1% vs 54.9%; P=0.003).Conclusion: Based on IMMPACT and OARSI-OMERACT criteria, the analgesic effect of duloxetine was associated with clinically relevant benefits in Chinese patients with OA of the knee/hip.ClinicalTrials.gov identifier: NCT01931475. Keywords: Chinese, chronic pain, duloxetine, clinical meaningfulness, efficacy, osteoarthritis |
| format |
article |
| author |
Yue L Luo S Wang Y Wang CN Dueñas HJ Skljarevski V |
| author_facet |
Yue L Luo S Wang Y Wang CN Dueñas HJ Skljarevski V |
| author_sort |
Yue L |
| title |
Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
| title_short |
Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
| title_full |
Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
| title_fullStr |
Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
| title_full_unstemmed |
Clinical meaningfulness of duloxetine's effect in Chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
| title_sort |
clinical meaningfulness of duloxetine's effect in chinese patients with chronic pain due to osteoarthritis: post hoc analyses of a phase 3 randomized trial |
| publisher |
Dove Medical Press |
| publishDate |
2019 |
| url |
https://doaj.org/article/939aa549f2e74d6ca13ae2fb7dd14a9b |
| work_keys_str_mv |
AT yuel clinicalmeaningfulnessofduloxetine39seffectinchinesepatientswithchronicpainduetoosteoarthritisposthocanalysesofaphase3randomizedtrial AT luos clinicalmeaningfulnessofduloxetine39seffectinchinesepatientswithchronicpainduetoosteoarthritisposthocanalysesofaphase3randomizedtrial AT wangy clinicalmeaningfulnessofduloxetine39seffectinchinesepatientswithchronicpainduetoosteoarthritisposthocanalysesofaphase3randomizedtrial AT wangcn clinicalmeaningfulnessofduloxetine39seffectinchinesepatientswithchronicpainduetoosteoarthritisposthocanalysesofaphase3randomizedtrial AT duenashj clinicalmeaningfulnessofduloxetine39seffectinchinesepatientswithchronicpainduetoosteoarthritisposthocanalysesofaphase3randomizedtrial AT skljarevskiv clinicalmeaningfulnessofduloxetine39seffectinchinesepatientswithchronicpainduetoosteoarthritisposthocanalysesofaphase3randomizedtrial |
| _version_ |
1718401871773696000 |